{"id":659386,"date":"2023-07-13T05:24:01","date_gmt":"2023-07-13T05:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=659386"},"modified":"2023-07-13T05:24:01","modified_gmt":"2023-07-13T05:24:01","slug":"inflammatory-myositis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-csl-behring-immunoforge-co-ltd-argenx-janssen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/inflammatory-myositis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-csl-behring-immunoforge-co-ltd-argenx-janssen_659386.html","title":{"rendered":"Inflammatory Myositis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies &#8211; CSL Behring, Immunoforge Co. Ltd., Argenx Janssen"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Inflammatory Myositis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - CSL Behring, Immunoforge Co. Ltd., Argenx Janssen\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Inflammatory Myositis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - CSL Behring, Immunoforge Co. Ltd., Argenx Janssen\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s \u201cInflammatory myositis (IM)- Market Insights, Epidemiology and Market Forecast\u2013 2032\u201d report delivers an in-depth understanding of the Inflammatory myositis, historical and forecasted epidemiology as well as the Inflammatory myositis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-myositis-im-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Inflammatory myositis (IM)- Market Insights, Epidemiology and Market Forecast&ndash; 2032<\/a><\/strong>&rdquo; report delivers an in-depth understanding of the Inflammatory myositis, historical and forecasted epidemiology as well as the Inflammatory myositis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Click here to learn more about the<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-myositis-im-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Inflammatory Myositisis Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Inflammatory Myositisis Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis diagnosed cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis incident cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Inflammatory Myositis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The treatment landscape for inflammatory myositis has evolved over the years. Current treatment approaches involve a combination of immunosuppressive medications, such as corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs) i.e. immunosuppressive agents, biologic agents, physical therapy, and supportive measures. However, there is still an unmet need for more effective and targeted therapies with fewer side effects. The development of novel treatments, including biologics and small molecule inhibitors, could significantly impact the market outlook by offering new options for patients.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">In light of the above, some developmental initiatives have been taken toward the management of IM. The condition may evolve as some interesting therapies are heading down the pipeline. This would encourage reimbursement scenarios, doctors&rsquo; adoption, and patient compliance. Some companies have initiated clinical trials investigating new treatment options, including Argenx (Efgartigimod), CSL Behring (Hizentra), Pfizer (PF-06823859), Priovant Therapeutics (Beprocitinib), and Alexion Pharmaceuticals (Ravulizumab) as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/5f8907fed2c42e861845923077b91664.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Key Companies Working in the Inflammatory Myositisis Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">CSL BehringImmunoforge Co. Ltd.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">ArgenxJanssenAbcuro, Inc.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Horizon Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Merck KGaA<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Inflammatory Myositis Therapies Covered and Analyzed in the Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Efgartigimod<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ciclosporin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Daxdilimab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Belimumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tofacitinib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Nipocalimab<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-myositis-im-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Inflammatory Myositisis&nbsp; Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Inflammatory Myositis&nbsp; &nbsp; &#8211;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis&nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inflammatory Myositis&nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/inflammatory-myositis-im-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Inflammatory Myositisis Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=inflammatory-myositis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-csl-behring-immunoforge-co-ltd-argenx-janssen\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=inflammatory-myositis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-csl-behring-immunoforge-co-ltd-argenx-janssen\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s \u201cInflammatory myositis (IM)- Market Insights, Epidemiology and Market Forecast\u2013 2032\u201d report delivers an in-depth understanding of the Inflammatory myositis, historical and forecasted epidemiology as well as the Inflammatory myositis market trends in the United States, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/inflammatory-myositis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-csl-behring-immunoforge-co-ltd-argenx-janssen_659386.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-659386","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/659386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=659386"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/659386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=659386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=659386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=659386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}